NASDAQ:KIN - Kindred Biosciences Stock Price, Forecast & News

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences Inc (NASDAQ:KIN) announced its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.55 million. Kindred Biosciences had a negative return on equity of 58.86% and a negative net margin of 1,461.28%. View Kindred Biosciences' Earnings History.

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Kindred Biosciences.

8 analysts have issued 12 month price targets for Kindred Biosciences' shares. Their forecasts range from $8.50 to $25.00. On average, they anticipate Kindred Biosciences' share price to reach $14.44 in the next year. This suggests a possible upside of 46.7% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

Media coverage about KIN stock has trended very negative recently, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kindred Biosciences earned a daily sentiment score of -3.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Kindred Biosciences.

Kindred Biosciences saw a drop in short interest during the month of February. As of February 14th, there was short interest totalling 647,300 shares, a drop of 14.0% from the January 30th total of 753,000 shares. Based on an average trading volume of 127,700 shares, the days-to-cover ratio is currently 5.1 days. Currently, 1.8% of the shares of the stock are short sold. View Kindred Biosciences' Current Options Chain.

Some companies that are related to Kindred Biosciences include Aimmune Therapeutics (AIMT), Akcea Therapeutics (AKCA), Zymeworks (ZYME), IGM Biosciences (IGMS), Alder Biopharmaceuticals (ALDR), Corcept Therapeutics (CORT), Constellation Pharmaceuticals (CNST), Endo International (ENDP), Amneal Pharmaceuticals (AMRX), Dicerna Pharmaceuticals (DRNA), Innoviva (INVA), ZEALAND PHARMA/S (ZEAL), Theravance Biopharma (TBPH), Madrigal Pharmaceuticals (MDGL) and Nabriva Therapeutics (NBRV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO).

Kindred Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Ariel Investments LLC (4.56%), Renaissance Technologies LLC (3.02%), State Street Corp (1.79%), General American Investors Co. Inc. (1.32%), Geode Capital Management LLC (1.21%) and UBS Group AG (0.37%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

KIN stock was sold by a variety of institutional investors in the last quarter, including Ariel Investments LLC, Goldman Sachs Group Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Kindred Biosciences.

KIN stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, State Street Corp, Cambridge Investment Research Advisors Inc., Edgewood Management LLC, UBS Group AG, General American Investors Co. Inc., Prudential Financial Inc. and Barclays PLC. View Insider Buying and Selling for Kindred Biosciences.

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KIN stock can currently be purchased for approximately $9.84.

Kindred Biosciences has a market capitalization of $384.65 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.

The official website for Kindred Biosciences is http://kindredbio.com/.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]